Key Highlights

  • Neogen (NASDAQ:NEOG) reported first quarter fiscal 2027 Revenue of USD 222.8 million on October 6, 2026, up 6.5% from USD 209.2 million, with core revenue growth of 8.1%.
  • Adjusted EPS was USD 0.08 versus USD 0.04 a year earlier, while the GAAP net loss was USD 11.9 million, or USD 0.05 per diluted share, on adjusted Net Income of USD 17.5 million.
  • Adjusted EBITDA was USD 41.6 million, an 18.7% margin, and fiscal 2027 revenue guidance rose to USD 885 million to USD 890 million from USD 880 million to USD 885 million.
  • Food Safety revenue grew 7.4% to USD 163.2 million and Animal Safety rose 4.2% to USD 59.6 million, so Neogen (NASDAQ:NEOG) grew in both segments in the quarter.

What Neogen Reported

Neogen (NASDAQ:NEOG) released first quarter fiscal 2027 results for the quarter ended August 31, 2026 on October 6, 2026. Revenue of USD 222.8 million rose 6.5%, or 8.1% on a core basis. Domestic revenue was USD 110.1 million and international revenue was USD 112.7 million. Adjusted EPS of USD 0.08 doubled from USD 0.04, though the company still posted a GAAP net loss of USD 11.9 million. Published market data cited a consensus near a loss of USD 0.07 per share and revenue near USD 208.2 million, but those estimates are reported and could not be confirmed, so the size of the beat is not verified.

How the Outlook Changed

Management raised fiscal 2027 revenue guidance by USD 5 million at each end, to USD 885 million to USD 890 million, and lifted adjusted EBITDA guidance to USD 181 million to USD 183 million from USD 180 million to USD 182 million. Those are small steps, equal to about 0.6% on the revenue midpoint by simple arithmetic. The mechanism is operating leverage: Neogen sells test kits and consumables that detect pathogens, allergens and residues in food and animal products, so recurring consumable Volume lifts margins when fixed costs are controlled. The release did not include EPS or EBITDA Margin guidance. CEO Mike Nassif described the quarter as encouraging progress and said the company is moving from strengthening fundamentals to scaling them.

Risks and Next Steps

The gap between a GAAP loss and positive adjusted profit is the main item to watch, because adjusted measures exclude charges that still cost cash. Food Safety grew faster than Animal Safety, so any slowdown in testing Demand would matter. Tariffs, currency and customer destocking are other risks. The next catalyst is the second quarter report, expected after the quarter ends November 30, 2026, though the date is not confirmed. Investors should compare Neogen (NASDAQ:NEOG) with larger testing peers and monitor leverage, since a raised range of this size leaves little cushion if core growth slips below roughly 8%. Share price reaction on October 7, 2026 was not verified. This is not Investment advice.

Where Things Stand

Neogen (NASDAQ:NEOG) raised its outlook because first quarter revenue and adjusted EBITDA ran ahead of plan, giving management room to lift the full-year revenue range by USD 5 million at each end. The increase is modest, and the GAAP net loss of USD 11.9 million shows that profitability is still being rebuilt. The balance of evidence is constructive but not decisive: core growth of 8.1% is solid, yet guidance omits EPS. The next Quarterly Report will show whether the trend holds.